Due to the cardiovascular and renal benefits of sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes (T2D), those with heart failure (HF), and those with chronic kidney disease (CKD), SGLT2is have been recommended in these populations to prevent cardiorenal events (1–3). Here, SLC5A2 is linked to type 2 diabetes mellitus.